264 related articles for article (PubMed ID: 26909268)
1. Incidence and consequences of bone metastases in lung cancer patients.
Kuchuk M; Addison CL; Clemons M; Kuchuk I; Wheatley-Price P
J Bone Oncol; 2013 Feb; 2(1):22-9. PubMed ID: 26909268
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
3. The incidence and clinical impact of bone metastases in non-small cell lung cancer.
Kuchuk M; Kuchuk I; Sabri E; Hutton B; Clemons M; Wheatley-Price P
Lung Cancer; 2015 Aug; 89(2):197-202. PubMed ID: 26003503
[TBL] [Abstract][Full Text] [Related]
4. Skeletal related events in patients with bone metastasis arising from non-small cell lung cancer.
da Silva GT; Bergmann A; Thuler LCS
Support Care Cancer; 2016 Feb; 24(2):731-736. PubMed ID: 26143039
[TBL] [Abstract][Full Text] [Related]
5. Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials.
LeVasseur N; Clemons M; Hutton B; Shorr R; Jacobs C
Cancer Treat Rev; 2016 Nov; 50():183-193. PubMed ID: 27716496
[TBL] [Abstract][Full Text] [Related]
6. Targeted treatments of bone metastases in patients with lung cancer.
Hirsh V
Front Oncol; 2014; 4():146. PubMed ID: 24982847
[TBL] [Abstract][Full Text] [Related]
7. Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort.
Conen K; Hagmann R; Hess V; Zippelius A; Rothschild SI
J Cancer; 2016; 7(14):2110-2116. PubMed ID: 27877227
[No Abstract] [Full Text] [Related]
8. Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data.
Zhang H; Zhu W; Biskup E; Yang W; Yang Z; Wang H; Qiu X; Zhang C; Hu G; Hu G
J Bone Oncol; 2018 Jun; 11():38-50. PubMed ID: 29511626
[TBL] [Abstract][Full Text] [Related]
9. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.
Langer C; Hirsh V
Lung Cancer; 2010 Jan; 67(1):4-11. PubMed ID: 19939491
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
[TBL] [Abstract][Full Text] [Related]
11. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
12. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.
D'Oronzo S; Coleman R; Brown J; Silvestris F
J Bone Oncol; 2019 Apr; 15():004-4. PubMed ID: 30937279
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
14. Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases.
Udagawa H; Niho S; Kirita K; Umemura S; Matsumoto S; Yoh K; Goto K
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1075-1082. PubMed ID: 28220258
[TBL] [Abstract][Full Text] [Related]
15. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.
Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K
Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
Bhowmik D; Song X; Intorcia M; Gray S; Shi N
Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
[TBL] [Abstract][Full Text] [Related]
18. Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
Sun JM; Ahn JS; Lee S; Kim JA; Lee J; Park YH; Park HC; Ahn MJ; Ahn YC; Park K
Lung Cancer; 2011 Jan; 71(1):89-93. PubMed ID: 20598769
[TBL] [Abstract][Full Text] [Related]
19. Bone metastases in non-small cell lung cancer: a narrative review.
Knapp BJ; Devarakonda S; Govindan R
J Thorac Dis; 2022 May; 14(5):1696-1712. PubMed ID: 35693589
[TBL] [Abstract][Full Text] [Related]
20. Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre.
Kuchuk I; Hutton B; Moretto P; Ng T; Addison CL; Clemons M
J Bone Oncol; 2013 Dec; 2(4):137-44. PubMed ID: 26909284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
